Retrospective cohort study reveals no link between standard tumor features and hemoptysis recurrence after arterial embolization in lung cancer, highlighting the need for vascular markers.
Key Points
Determine whether baseline clinical and tumor characteristics can identify patients at higher risk of hemoptysis recurrence following arterial embolization for lung malignancy.
Conducted a 5-year single-center retrospective cohort study of 126 consecutive patients with histologically confirmed lung cancer treated with arterial embolization for hemoptysis (January 2021 to December 2025).
Embolic agents included metallic microcoils, polyvinyl alcohol particles (300–700 μm), gelatin sponge, or combinations of these materials.
Assessed recurrence-free intervals and five prespecified covariates (tumor diameter, cancer stage, histological subtype, age, and sex) using Kaplan-Meier analysis and multivariable Cox proportional hazards regression.
Major complications occurred in 2.4% of patients (3/126), with no procedure-related mortality or permanent neurological deficits reported.
None of the evaluated baseline clinical or tumor characteristics—including tumor diameter, cancer stage, histological subtype, age, or sex—demonstrated a statistically significant association with hemoptysis recurrence.